Episode 61
Biotech Hangout
00:00
Sorepta's FDA Update
The company also expects to complete enrollment in a phase three trial for their program in spinal muscular atrophy this year. Chris, you were the former CEO of Sorepta, among your many other distinctions. Can you provide any context around last week's Sorepta FDA update?
Transcript
Play full episode
